Current Treatment Options for Renal Cell Carcinoma: Focus on Cell-Based Immunotherapy

Author:

Hwang Angela12ORCID,Mehra Vedika2,Chhetri Jyoti2,Ali Samira2,Tran Maxine34,Roddie Claire12ORCID

Affiliation:

1. Department of Haematology, University College Hospital, University College London Hospitals NHS Foundation Trust, London NW1 2BU, UK

2. University College London Cancer Institute, 72 Huntley Street, London WC1E 6DD, UK

3. University College London Division of Surgery and Interventional Science, Rowland Street, London NW3 2QG, UK

4. The Specialist Centre for Kidney Cancer, Royal Free Hospital, Pond Street, London NW3 2QG, UK

Abstract

Renal cell carcinoma (RCC) affects over 400,000 patients globally each year, and 30% of patients present with metastatic disease. Current standard of care therapy for metastatic RCC involve TKIs and ICIs, including combinatorial strategies, but this offers only modest clinical benefit. Novel treatment approaches are warranted, and cell-based immunotherapies for RCC hold significant promise. These are currently being tested in the pre-clinical setting and in early phase clinical trials. Here, we review the landscape of cellular immunotherapy for RCC in the context of currently available therapies, with a particular focus on defining the current best antigenic targets, the range of cell therapy products being explored in RCC, and how advanced engineering solutions may further enhance these therapies in the RCC space.

Publisher

MDPI AG

Reference134 articles.

1. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA;Sung;Cancer J. Clin.,2021

2. Cancer Statistics, 2023. CA;Siegel;Cancer J. Clin.,2023

3. (2023, December 05). Kidney Cancer Incidence Statistics. Available online: https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/kidney-cancer/incidence.

4. (2024, January 10). Cancer of the Kidney and Renal Pelvis—Cancer Stat Facts, Available online: https://seer.cancer.gov/statfacts/html/kidrp.html.

5. Renal-Cell Carcinoma;Motzer;N. Engl. J. Med.,1996

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3